Gennex Laboratories Ltd manufactures Bulk Drugs and IntermediariesBusiness Overview: GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants, Muscle Relaxants, Analgesic and Anti Fungal, etc.
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication of AGM Notice and eVoting related instructions advertisement published in ....
With reference to the subject matter, As per the Regulation 34 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submits 41st Annual Report of Gennex ....
Gennex Laboratories has set a book closure period for its 41st Annual General Meeting, which is scheduled for September 30, 2026. The company's Register of Members and Share Transfer Books will be closed from September 23 to September 30, 2026, inclusive. This action is crucial for identifying shareholders eligible to...
Gennex Labs' Board met and approved reports for FY26. The 41st AGM is set for Sep 30, 2026, via video conference. E-voting period is Sep 27-29, with book closure Sep 23-30.
Gennex Laboratories has announced a board meeting on September 04, 2026. Key agenda items include finalizing details for the 41st Annual General Meeting (AGM) for FY26 and appointing an AGM scrutinizer.
